Hyderabad, India, August 13, 2024 – CiVentiChem, a leading contract development and manufacturing organization (CDMO) for over 30 years, proudly announces the completion of a new facility, significantly expanding its manufacturing capacity by 300%. This state-of-the-art facility will focus on producing Regulatory Starting Materials (RSMs) and intermediates to support small molecule clinical and commercial needs.
“It’s a major evolution for the company,” stated Bhaskar Venepalli, CEO of CiVentiChem. “The decision to invest in a second manufacturing plant was driven by our customers and recent international developments. We’ve seen an increasing number of clients seeking alternative manufacturers outside of China for RSMs and intermediates. We’re thrilled to support the growing manufacturing needs of our clients.”
This milestone coincides with CiVentiChem's 30th anniversary. Founded in North Carolina in 1994, the company initially offered medicinal chemistry and FTE services. In 2001, CiVentiChem opened their first R&D facility in Hyderabad, India. CiVentiChem expanded to larger scale manufacturing in 2009, manufacturing RSMs for clinical programs and three commercial programs.
In 2019, CiVentiChem sold its US operations which included GMP manufacturing to Sterling Pharma but continued its operations in India. Dr. Srinivas “Vasu” Chittineni, Co-Founder and Managing Director, relocated from North Carolina to India to manage the plant. Meanwhile, Co-Founder and CEO Bhaskar Venepalli remained in North Carolina, establishing an office for sales and the logistics of shipping and receiving materials from India.
“Today’s announcement regarding our expanding manufacturing capabilities marks a historic achievement in the 30-year history of our company,” stated Dr. Vasu Chittineni.
